Venclose

About Venclose

Venclose, founded in 2014, operates in the medical technology sector, focusing on treatments for chronic venous insufficiency (CVI). The company was established to address the unmet needs of physicians by improving upon existing radiofrequency (RF) ablation technology that had seen little advancement in over a decade. In December 2021, Venclose was acquired by BD (Becton, Dickinson and Company), a major global medical technology firm, to enhance BD's portfolio in venous disease treatment. Prior to its acquisition, Venclose had secured significant venture capital, including a $27.1 million Series C round in November 2019 led by Ally Bridge Group.

The company's core business revolves around the development and commercialization of its RF ablation system for treating venous reflux disease, a condition affecting a significant portion of the adult population. Its clients are healthcare providers and physicians in vein practices and other healthcare settings across the United States and parts of Europe. The business model is centered on the sale of its medical devices to these clinical customers.

Venclose's flagship product is the VENCLOSE™ RF Ablation System, a minimally invasive solution for CVI. This system is composed of a proprietary generator and a specialized catheter. A key feature is its single catheter design that incorporates two different heating length sizes (2.5 cm and 10 cm), allowing physicians to treat both long and short segments of a diseased vein without switching instruments. This dual-length capability aims to increase procedural efficiency, reduce the total number of ablations needed, and simplify inventory management for clinics. The system also features a compact generator with a touchscreen interface that provides real-time data and audible tones during thermal delivery, allowing clinicians to focus more on the patient. In October 2021, the company received FDA 510(k) clearance for the Venclose Maven™, a catheter specifically designed for treating incompetent perforator veins, further expanding its product offerings.